Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Dow
Baxter
Boehringer Ingelheim
AstraZeneca
Express Scripts

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Penicillamine - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Drug Prices for penicillamine

See drug prices for penicillamine

Recent Clinical Trials for penicillamine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEarly Phase 1
GMP-Orphan SASPhase 3
Ankara UniversityN/A

See all penicillamine clinical trials

Pharmacology for penicillamine
Medical Subject Heading (MeSH) Categories for penicillamine
Synonyms for penicillamine
(-)-Penicillamine
(2S)-2-amino-3-mercapto-3-methyl-butyric acid
(2S)-2-amino-3-mercapto-3-methyl-butyric acid;hydrochloride
(2S)-2-amino-3-mercapto-3-methylbutanoic acid
(2S)-2-amino-3-mercapto-3-methylbutanoic acid;hydrochloride
(2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid
(2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid
(2S)-2-amino-3-methyl-3-sulfanylbutanoic acid;hydrochloride
(2S)-2-amino-3-methyl-3-sulfanylbutanoic acid3-sulfanyl-D-valine
(2S)-2-azanyl-3-methyl-3-sulfanyl-butanoic acid
(2S)-2-azanyl-3-methyl-3-sulfanyl-butanoic acid;hydrochloride
(D)-PENICILLAMINE
(S)-2-amino-3-mercapto-3-methylbutanoic acid
(S)-3,3-Dimethylcysteine
(S)-Penicillamin
(S)-Penicillamine
064P302
16414-54-3
24217-EP2272832A1
24217-EP2281815A1
24217-EP2301933A1
24217-EP2305640A2
24217-EP2311827A1
24217-EP2311842A2
24217-EP2314590A1
24217-EP2371811A2
24217-EP2380872A1
3-Mercapto-D-valine
3-sulfanyl-D-valine
3,3-Dimethyl-D-cysteine
3,3-Dimethyl-D(-)-cysteine
52-67-5
771431-20-0
937590-88-0
AB0010552
AB2000333
AC1L1L9Z
AC1Q1NP9
AC1Q1NPA
AJ-11468
AK170110
AKOS006237201
alpha-Amino-beta-methyl-beta-mercaptobutyric acid
AM83710
AN-17300
ANW-31517
Artamine
BCP17247
BDBM39346
BDBM50217941
beta-Thiovaline
beta,beta-Dimethylcysteine
BSPBio_002181
C07418
CAS-52-67-5
CCRIS 2904
CHEBI:7959
CHEMBL1430
cid_92173
Copper penicillaminate
CPD000653530
CS-2334
CTK1G9784
Cuprenil
Cuprimine
Cuprimine (TN)
Cupripen
D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid
D-(-)-Penicillamine
D-3-Mercaptovaline
D-beta-Mercaptovaline
D-beta,beta-Dimethylcysteine
D-Mercaptovaline
D-Penamine
D-Penicilamine
D-Penicillamine
D-Penicillamine, 98-101%
D-Penicyllamine
D-Valine, 3-mercapto-
d,3-Mercaptovaline
D(-)-Penicillamine, 99%, specified according to Ph.Eur. and USP
D00496
DB00859
Depamine
Depen
Depen (TN)
Depen;Distamine;D-Mercaptovaline;D-Penamine;Kuprenil;Cuprimine
Dimethylcysteine
Distamine
Distamine (*Hydrochloride*)
DivK1c_000314
DSSTox_CID_17069
DSSTox_GSID_37069
DSSTox_RID_79300
DTXSID6037069
EINECS 200-148-8
EN300-52608
Epitope ID:113237
FT-0624341
GNN1DV99GX
GTPL7264
H-D-Pen-OH
HSDB 3378
HY-B0300
IDI1_000314
K-9599
KB-50430
KBio1_000314
KBio2_000763
KBio2_003331
KBio2_005899
KBio3_001681
KBioGR_000920
KBioSS_000763
KS-000001ON
Kuprenil
LS-161321
MCULE-5986342172
Mercaptovaline
Mercaptyl
Metalcaptase
Metalcaptase (*Hydrochloride*)
MFCD00064302
MolPort-001-792-382
NCGC00018283-01
NCGC00024359-04
NCGC00024359-05
NCGC00024359-06
NINDS_000314
NSC 81549
NSC81549
P-1280
P0147
Pendramine
Penicilamina
Penicilamina [INN-Spanish]
Penicillamin
Penicillamina
Penicillamina [DCIT]
Penicillamine (Cuprimine)
Penicillamine (JAN/USP/INN)
Penicillamine [USAN:INN:BAN:JAN]
Penicillamine [USAN:USP:INN:BAN:JAN]
Penicillamine, European Pharmacopoeia (EP) Reference Standard
Penicillamine, United States Pharmacopeia (USP) Reference Standard
Penicillamine,(S)
Penicillaminum
Penicillaminum [INN-Latin]
Penicilllamine
Perdolat
Reduced D-penicillamine
Reduced penicillamine
RL03939
RTR-032192
s1853
SAM002548964
SCHEMBL4343
SMP1_000042
SPBio_001217
Spectrum_000283
Spectrum2_001029
Spectrum3_000541
Spectrum4_000470
Spectrum5_001196
SR-01000000262
SR-01000000262-3
SR-01000000262-4
STR02534
Sufirtan
Sufortan
Tox21_110899
TR-032192
Trolovol
UNII-2XOP7Y1H98 component VVNCNSJFMMFHPL-VKHMYHEASA-N
UNII-GNN1DV99GX
Valine, 3-mercapto-, D-
VVNCNSJFMMFHPL-VKHMYHEASA-N
ZINC100509167
ZINC114127

US Patents and Regulatory Information for penicillamine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amerigen Pharms Ltd PENICILLAMINE penicillamine CAPSULE;ORAL 209921-001 May 7, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Valeant Pharms Intl CUPRIMINE penicillamine CAPSULE;ORAL 019853-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs Inc PENICILLAMINE penicillamine CAPSULE;ORAL 210976-001 Jun 24, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Moodys
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.